Improving Cancer Care through Broader Access to Quality Biomarker Testing – An IQN Path, ECPC and EFPIA Initiative
Normanno, et al.
To address the barriers to high quality BMT, multi-disciplinary and concerted action is needed. Short-term and long-term policy recommendations to address the shortcomings in BMT access would be presented and discussed with the ESMO audience. The project was initiated and financed by IQN Path, ECPC and EFPIA together with a consortium of industry and academic partners, and conducted by L.E.K. Consulting.
Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result
Tüchler, et al.
Integrating PRS and NGRF for risk calculation led to (1) an increase in patients eligible for IBS and (2) a recommendation change for every fifth woman. When switching country guideline, clinical recommendations changed for a quarter of women (CR). Prospective validation studies, as well as evaluating and harmonizing guidelines are necessary.
Selection of quality indicators (QI) by non-hospital professionals for onco-hematology care pathway
di Palma, et al.
A final step will consist in gathering all the actors (hospital professionals, patient associations and non-hospital professionals) and comparing the QIs selected by each group in order to obtain a final and common set of QIs. These QIs could then be tested in the institutions of the project participants in order to validate their metrological qualities.
Rationalizing the use of off-label drugs (OLD) within a spEcial Medication (ME) program for cancer patients (pt): the Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore).
Notario Rincon, et al.
ICO MEscore is the first prognostic index under development for ME pt selection and our results suggest that could serve to identify HR pt with dismal prognosis. Further validation is warranted to confirm its applicability to rationalize ME decision- making.
Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials
J.T. Moyers, et al.
The FDA guidance for co-development provides a useful framework to evaluate combos, but only 57% of combos met all criteria. There are differences in adherence to the FDA guidance and use of biomarkers between IO and TT combos.
European cancer patients’ perspectives on Immunotherapy
Kosmidis, et al.
Most patients do not know enough about immunotherapy, its mechanism and timing of action, and its costs to the healthcare system. Among 4 cancer types, lung cancer patients (especially those treated with immunotherapy) are better informed.